(Q35109112)

6 August 2017

1 reference

title

Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? (English)

1 reference

6 August 2017

Is There a Role for ??-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus? (English)

1 reference

https://api.crossref.org/works/10.2165/00003495-200363100-00002

25 December 2023

1 reference

glycoside hydrolase inhibitors

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699398

25 December 2023

author name string

André J. Scheen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699398

25 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12699398

25 December 2023

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

63

1 reference

6 August 2017

10

1 reference

6 August 2017

933-951

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363100-00002

6 August 2017

0 references

cites work

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

12 December 2020

The clinical implications of impaired glucose tolerance

1 reference

12 December 2020

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.

1 reference

12 December 2020

Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.

1 reference

12 December 2020

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

1 reference

12 December 2020

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

12 December 2020

Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects

1 reference

12 December 2020

alpha-Glucosidase inhibition in obesity.

1 reference

12 December 2020

The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century

1 reference

12 December 2020

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

1 reference

12 December 2020

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

1 reference

12 December 2020

Clinical experience with acarbose as first line therapy in NIDDM.

1 reference

12 December 2020

[Role of acarbose in the treatment of diabetes mellitus]

1 reference

12 December 2020

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

12 December 2020

Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.

1 reference

12 December 2020

Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

12 December 2020

Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study

1 reference

12 December 2020

Oral antidiabetic agents. A guide to selection

1 reference

12 December 2020

Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.

1 reference

12 December 2020

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

12 December 2020

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

12 December 2020

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

1 reference

12 December 2020

1 reference

12 December 2020

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

1 reference

12 December 2020

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

12 December 2020

Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

1 reference

12 December 2020

Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

Orlistat: in the prevention and treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

12 December 2020

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

1 reference

12 December 2020

Prevention of diabetes mellitus. Report of a WHO Study Group

1 reference

12 December 2020

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

12 December 2020

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

12 December 2020

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

12 December 2020

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

1 reference

12 December 2020

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

12 December 2020

The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.

1 reference

12 December 2020

Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia

1 reference

12 December 2020

Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight

1 reference

12 December 2020

Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.

1 reference

12 December 2020

The benefits of modest weight loss in type II diabetes

1 reference

12 December 2020

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

12 December 2020

Acarbose for type 2 diabetes prevention

1 reference

12 December 2020

Drug therapy of postprandial hyperglycaemia.

1 reference

12 December 2020

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

1 reference

12 December 2020

Preventing long term complications. Implications for combination therapy with acarbose

1 reference

12 December 2020

Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes

1 reference

12 December 2020

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus

1 reference

12 December 2020

Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.

1 reference

12 December 2020

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

1 reference

12 December 2020

The impact of pharmacotherapy on weight management in type 2 diabetes

1 reference

12 December 2020

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

12 December 2020

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

12 December 2020

Oral therapies for diabetic hyperglycemia

1 reference

12 December 2020

Improving the action of insulin.

1 reference

12 December 2020

Diet and risk of Type II diabetes: the role of types of fat and carbohydrate

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

1 reference

12 December 2020

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

1 reference

12 December 2020

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

1 reference

12 December 2020

Marked weight loss in a type 2 diabetic patient treated with acarbose

1 reference

12 December 2020

Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes

1 reference

12 December 2020

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

1 reference

12 December 2020

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

1 reference

12 December 2020

The postprandial state and risk of cardiovascular disease

1 reference

12 December 2020

1 reference

12 December 2020

Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients

1 reference

12 December 2020

Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects

1 reference

12 December 2020

An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group

1 reference

12 December 2020

Ramipril and the development of diabetes.

1 reference

12 December 2020

Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.

1 reference

12 December 2020

The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics.

1 reference

12 December 2020

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision-analytical approach

1 reference

12 December 2020

Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM

1 reference

12 December 2020

Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity

1 reference

12 December 2020

The prevention or delay of type 2 diabetes

1 reference

12 December 2020

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance

1 reference

12 December 2020

Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.

1 reference

12 December 2020

Accurate assessment of beta-cell function: the hyperbolic correction

1 reference

12 December 2020

Miglitol: assessment of its role in the treatment of patients with diabetes mellitus

1 reference

12 December 2020

Acarbose and nutrient intake in non-insulin dependent diabetes mellitus.

1 reference

12 December 2020

Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo

1 reference

12 December 2020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships of Acarbose

1 reference

12 December 2020

Predictors of persistence of use of the novel antidiabetic agent acarbose

1 reference

12 December 2020

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

1 reference

12 December 2020

Hyperleptinaemia: the missing link in the, metabolic syndrome?

1 reference

12 December 2020

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

1 reference

12 December 2020

Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.

1 reference

12 December 2020

Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes

1 reference

12 December 2020

The mechanism of alpha-glucosidase inhibition in the management of diabetes

1 reference

12 December 2020

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve

1 reference

12 December 2020

Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients

1 reference

12 December 2020

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

12 December 2020

Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.

1 reference

12 December 2020

Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects

1 reference

12 December 2020

Effects of the alpha-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic implications

1 reference

12 December 2020

Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study

1 reference

12 December 2020

31

15

415

Yki-Jarvinen

1992

1 reference

https://api.crossref.org/works/10.2165/00003495-200363100-00002

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

25 December 2023

series ordinal

88

1 reference

https://api.crossref.org/works/10.2165/00003495-200363100-00002

The International Diabetes website

25 December 2023

series ordinal

95

1 reference

https://api.crossref.org/works/10.2165/00003495-200363100-00002

25 December 2023

Identifiers

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference